Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate ...

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Investment analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Gossamer Bio in a report issued on Monday, March 24th.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...

Gossamer Bio has a one year low of $0.50 and a one year high of $1.60. The stock has a market cap of $278.72 million, a PE ratio of -3.84 and a beta of 1.81. The firm has a 50 day simple moving ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...